JP2013514308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514308A5 JP2013514308A5 JP2012543701A JP2012543701A JP2013514308A5 JP 2013514308 A5 JP2013514308 A5 JP 2013514308A5 JP 2012543701 A JP2012543701 A JP 2012543701A JP 2012543701 A JP2012543701 A JP 2012543701A JP 2013514308 A5 JP2013514308 A5 JP 2013514308A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ethyl
- oxadiazol
- tetrazol
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyrazol-4-yl Chemical group 0.000 claims 253
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 34
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 31
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 230000001154 acute effect Effects 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 2
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229940082657 digitalis glycosides Drugs 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229960001123 epoprostenol Drugs 0.000 claims 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 239000000938 histamine H1 antagonist Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 239000003580 lung surfactant Substances 0.000 claims 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 2
- 229960003073 pirfenidone Drugs 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 2
- 229960004617 sapropterin Drugs 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 claims 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 claims 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims 1
- SUCDHPJUXCCMDN-UHFFFAOYSA-N 2-ethyl-1,3-oxazole Chemical group CCC1=NC=CO1 SUCDHPJUXCCMDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179982 | 2009-12-18 | ||
| EP09179982.5 | 2009-12-18 | ||
| US31555210P | 2010-03-19 | 2010-03-19 | |
| US61/315,552 | 2010-03-19 | ||
| PCT/EP2010/069704 WO2011073231A1 (en) | 2009-12-18 | 2010-12-15 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514308A JP2013514308A (ja) | 2013-04-25 |
| JP2013514308A5 true JP2013514308A5 (https=) | 2014-02-06 |
| JP5645961B2 JP5645961B2 (ja) | 2014-12-24 |
Family
ID=41718903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543701A Expired - Fee Related JP5645961B2 (ja) | 2009-12-18 | 2010-12-15 | ３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ−［４，３−ｃ］イソキノリン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9018175B2 (https=) |
| EP (2) | EP2813509B1 (https=) |
| JP (1) | JP5645961B2 (https=) |
| KR (1) | KR20120123313A (https=) |
| CN (1) | CN102652136B (https=) |
| AR (1) | AR079451A1 (https=) |
| AU (1) | AU2010332955B8 (https=) |
| BR (1) | BR112012014058A8 (https=) |
| CA (1) | CA2784013A1 (https=) |
| CO (1) | CO6551705A2 (https=) |
| DK (1) | DK2513119T3 (https=) |
| EA (1) | EA023212B1 (https=) |
| ES (2) | ES2621291T3 (https=) |
| GE (1) | GEP20146105B (https=) |
| HR (1) | HRP20140893T1 (https=) |
| ME (1) | ME01914B (https=) |
| MX (1) | MX2012006696A (https=) |
| NZ (1) | NZ601115A (https=) |
| PH (1) | PH12012501125A1 (https=) |
| PL (1) | PL2513119T3 (https=) |
| PT (1) | PT2513119E (https=) |
| RS (1) | RS53544B1 (https=) |
| SG (2) | SG196785A1 (https=) |
| SI (1) | SI2513119T1 (https=) |
| SM (1) | SMT201400185B (https=) |
| TW (1) | TWI468411B (https=) |
| UA (1) | UA107689C2 (https=) |
| WO (1) | WO2011073231A1 (https=) |
| ZA (1) | ZA201204135B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110300432A1 (en) | 2010-06-07 | 2011-12-08 | Snyder Shawn W | Rechargeable, High-Density Electrochemical Device |
| EP2749283A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and olodaterol |
| EP2721036B1 (en) | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| WO2014090990A1 (en) * | 2012-12-13 | 2014-06-19 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| EP2951161A1 (en) | 2013-02-04 | 2015-12-09 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| PL3177624T3 (pl) | 2014-08-06 | 2019-09-30 | Pfizer Inc. | Związki imidazopirydazynowe |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899494A (en) | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
| DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH01213284A (ja) | 1988-02-22 | 1989-08-28 | Sankyo Co Ltd | チエノピリミジン−２，４−ジオン誘導体 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DE407028T1 (de) | 1989-05-31 | 1994-03-17 | Fisons Plc | Medikament und Inhalationsvorrichtung dafür. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| AU654813B2 (en) | 1990-03-23 | 1994-11-24 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| JP2769925B2 (ja) | 1990-10-18 | 1998-06-25 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤 |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of medicament formulations |
| EE03829B1 (et) | 1996-11-11 | 2002-08-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Bensonaftüridiinid, nende kasutamine bronhiaalravimi valmistamiseks ning neid sisaldav ravim |
| EP0986562B1 (en) | 1997-05-08 | 2002-08-07 | MERCK SHARP & DOHME LTD. | Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
| CA2291153A1 (en) | 1997-06-03 | 1998-12-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
| CN1150890C (zh) | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| JP4677102B2 (ja) | 1999-04-23 | 2011-04-27 | バテル・メモリアル・インスティテュート | エーロゾル給送装置及びエーロゾル小滴を給送する方法 |
| AU777169B2 (en) | 1999-04-23 | 2004-10-07 | Battelle Memorial Institute | High mass transfer electrosprayer |
| AU7961100A (en) | 1999-10-28 | 2001-05-08 | Daiichi Pharmaceutical Co., Ltd. | Drug discharge pump inhibitors |
| WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| WO2002005616A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
| CA2425035A1 (en) | 2000-10-09 | 2002-04-18 | 3M Innovative Properties Company | Medicinal aerosol formulations |
| CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| US20050239867A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| CA2579000C (en) * | 2004-09-08 | 2013-02-05 | Altana Pharma Ag | Novel 3-thia-10-aza-phenanthrene derivatives |
| JP5009799B2 (ja) * | 2004-09-08 | 2012-08-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の３−オキサ−１０−アザ−フェナントレン |
| WO2006054560A1 (ja) | 2004-11-17 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
| CA2599368A1 (en) * | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
| KR20100015886A (ko) * | 2007-04-23 | 2010-02-12 | 사노피-아벤티스 | Ｐ2ｙ12 길항제로서의 퀴놀린-카복스아미드 유도체 |
| EP2721036B1 (en) * | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
-
2010
- 2010-12-14 AR ARP100104617A patent/AR079451A1/es unknown
- 2010-12-15 SG SG2014000335A patent/SG196785A1/en unknown
- 2010-12-15 PL PL10790569T patent/PL2513119T3/pl unknown
- 2010-12-15 PT PT107905697T patent/PT2513119E/pt unknown
- 2010-12-15 ES ES14164018.5T patent/ES2621291T3/es active Active
- 2010-12-15 UA UAA201208482A patent/UA107689C2/ru unknown
- 2010-12-15 EP EP14164018.5A patent/EP2813509B1/en active Active
- 2010-12-15 JP JP2012543701A patent/JP5645961B2/ja not_active Expired - Fee Related
- 2010-12-15 AU AU2010332955A patent/AU2010332955B8/en not_active Ceased
- 2010-12-15 MX MX2012006696A patent/MX2012006696A/es active IP Right Grant
- 2010-12-15 BR BR112012014058A patent/BR112012014058A8/pt not_active IP Right Cessation
- 2010-12-15 RS RSP20140499 patent/RS53544B1/sr unknown
- 2010-12-15 EP EP10790569.7A patent/EP2513119B1/en active Active
- 2010-12-15 KR KR1020127017957A patent/KR20120123313A/ko not_active Withdrawn
- 2010-12-15 HR HRP20140893AT patent/HRP20140893T1/hr unknown
- 2010-12-15 SI SI201030746T patent/SI2513119T1/sl unknown
- 2010-12-15 SG SG2012034732A patent/SG180824A1/en unknown
- 2010-12-15 NZ NZ601115A patent/NZ601115A/en not_active IP Right Cessation
- 2010-12-15 ES ES10790569.7T patent/ES2505290T3/es active Active
- 2010-12-15 WO PCT/EP2010/069704 patent/WO2011073231A1/en not_active Ceased
- 2010-12-15 US US13/515,214 patent/US9018175B2/en not_active Expired - Fee Related
- 2010-12-15 GE GEAP201012783A patent/GEP20146105B/en unknown
- 2010-12-15 PH PH1/2012/501125A patent/PH12012501125A1/en unknown
- 2010-12-15 ME MEP-2014-114A patent/ME01914B/me unknown
- 2010-12-15 CN CN201080057293.7A patent/CN102652136B/zh not_active Expired - Fee Related
- 2010-12-15 EA EA201200891A patent/EA023212B1/ru not_active IP Right Cessation
- 2010-12-15 CA CA2784013A patent/CA2784013A1/en not_active Abandoned
- 2010-12-15 DK DK10790569.7T patent/DK2513119T3/da active
- 2010-12-17 TW TW99144591A patent/TWI468411B/zh not_active IP Right Cessation
-
2012
- 2012-05-24 CO CO12085785A patent/CO6551705A2/es active IP Right Grant
- 2012-06-06 ZA ZA2012/04135A patent/ZA201204135B/en unknown
-
2014
- 2014-12-11 SM SM201400185T patent/SMT201400185B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514308A5 (https=) | ||
| HRP20140893T1 (hr) | Derivati 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]izokinolina | |
| RU2352568C2 (ru) | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 | |
| JP2015533157A5 (https=) | ||
| US8420655B2 (en) | Benzimidazole inhibitors of leukotriene production | |
| JP2014525444A5 (https=) | ||
| US9174980B2 (en) | Heterocyclic compounds as inhibitors of leukotriene production | |
| JP2009526081A5 (https=) | ||
| JP2018535999A5 (https=) | ||
| JP2019517455A5 (https=) | ||
| JP2007523208A5 (https=) | ||
| JP2013517281A5 (https=) | ||
| IL303196A (en) | Heteroaryl-substituted pyridines and methods of use | |
| US8367679B2 (en) | Biaryl carboxamides | |
| JP2013512910A5 (https=) | ||
| HRP20120281T1 (hr) | Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3 | |
| JP2006502134A5 (https=) | ||
| JP2010526106A5 (https=) | ||
| JP2013517278A5 (https=) | ||
| JP2020520354A5 (https=) | ||
| CA2747419A1 (en) | Sulfonamide derivatives | |
| JP2017532364A5 (https=) | ||
| JP2015517580A5 (https=) | ||
| JP4465195B2 (ja) | 新規化合物 | |
| JP2010502615A5 (https=) |